Iodixanol in Multidetector-Row Computed Tomography-Coronary Angiography (MDCT-CA)

General Electric (GE)

Status and phase: Completed; Phase 4

Conditions: Coronary Artery Disease

Treatments: Drug: Iodixanol 320 mg I/Ml

Study type: Interventional

Funder types: Industry

Identifiers

NCT00209404

DXV407

Details and patient eligibility

About

Image quality in coronary artery computed tomography is influenced by the heart rate variation during the examination. The purpose of this clinical trial is to investigate the change in heart rate following injection of a contrast medium called Visipaque™ (iodixanol). Image quality and diagnostic quality of the examination will be evaluated.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects with low to moderate suspicion of coronary artery disease referred for retrospective electrocardiogram (ECG)-gated multidetector row computed tomography coronary angiography and with a heart rate >75 beats per minute (bpm) will be included.

Exclusion criteria

• Subjects who take medications that slow down the heart rate or present cardiac arrhythmia at rest will not be included.

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)